The research, led by Hyman B. Muss of the University of North Carolina at Chapel Hill and Mina S. Sedrak of UCLA, together with colleagues at City of Hope and the Mayo Clinic, examined 251 women with early-stage breast cancer and 49 cancer-free controls. The team measured p16INK4a, a gene whose expression rises as cells enter senescence—a state of permanent growth arrest linked to aging and disease—and compared it against five DNA methylation clocks: Horvath, Hannum, PhenoAge, GrimAge, and the Dunedin Pace of Aging, known as mPoA. DNA methylation clocks estimate biological age from characteristic patterns of chemical tags on DNA that shift predictably over a lifetime.

The two biomarker families barely spoke to each other. Across both cancer patients and controls, correlations between T-cell p16 and the methylation clocks were weak, with correlation coefficients generally below 0.3. In the cancer cohort, p16 showed only modest associations with Hannum, PhenoAge, and GrimAge, and none at all with the Horvath clock or the Dunedin pace measure. The pattern held in the control group and in a separate cohort of younger patients, where the strongest relationship—between p16 and GrimAge—reached only a moderate correlation of 0.40. The Dunedin measure, which estimates the rate of aging rather than accumulated age, showed essentially no relationship with p16 anywhere.

That disconnect matters because researchers and clinicians increasingly rely on these tests to gauge whether diseases or treatments are accelerating aging, and to evaluate interventions meant to slow it down. If p16 and methylation clocks captured the same underlying biology, they could be used interchangeably. The new findings suggest they cannot. The authors argue that the two measures reflect fundamentally different aspects of aging: p16 tracks senescence within a specific immune cell population, while methylation clocks integrate epigenetic signals across the heterogeneous mixture of cell types found in whole blood. Differences in biological compartment, measurement scale, and clock design—all calibrated differently, some to chronological age and others to mortality risk—likely all contribute to the weak overlap.

The study also probed whether cancer itself leaves a measurable imprint on these markers. When the researchers plotted biomarker levels against chronological age, women with breast cancer did not differ from controls in p16, Hannum, Horvath, or the Dunedin pace measure. But two of the mortality-informed clocks told a different story: GrimAge and PhenoAge were both significantly higher in the cancer group, and the differences persisted after adjusting for race, ethnicity, and body mass index. The result aligns with a growing body of evidence that cancer is associated with physiological changes consistent with accelerated aging, while suggesting that standard epigenetic clocks are not uniformly sensitive to that signal.

The most striking results came from the longitudinal arm. In a subset of 48 women with early breast cancer who gave blood before and three to six months after adjuvant chemotherapy, p16 expression rose significantly, by an average of 0.7 log2 units—an increase the authors note is equivalent to roughly 10 to 20 years of chronological aging. Yet four of the five methylation clocks—Horvath, PhenoAge, GrimAge, and the Dunedin pace—showed no significant change over the same interval. Only the Hannum clock increased, and only modestly. When the team split patients into those whose p16 rose beyond assay precision and those whose did not, none of the epigenetic clocks changed in either group, underscoring that the chemotherapy signal seen in senescence markers simply was not mirrored in the methylation-based measures.

The findings complicate the interpretation of earlier studies. Some prior work reported epigenetic age acceleration after cancer treatment: one study of breast cancer survivors found those who received chemotherapy were biologically two to three years older than controls two to three years after treatment, and a small study of 18 patients reported acceleration of roughly 3.5 to 8 years after a single anthracycline-containing cycle, though that analysis lacked paired samples. Other research found clock changes only years or decades later, or no change at all depending on regimen and follow-up timing. The new data suggest methylation clocks are not blind to treatment-related aging effects, but may respond on a different timescale or capture different biological consequences than the rapid senescence response registered by p16.

The team also explored senescence-associated secretory phenotype proteins—inflammatory molecules shed by senescent cells that have been linked to morbidity and mortality. In 20 patients treated with doxorubicin-based chemotherapy, chemotherapy-induced increases in p16 correlated with rising levels of PARC, TNFRII, ICAM1, and TNF-alpha. Intriguingly, baseline p16 showed little to no association with baseline levels of these proteins, suggesting the link is driven by the chemotherapy itself. Together with prior work showing increased p16, DNA damage, and inflammatory markers in survivors over two years, the results paint a picture in which cytotoxic chemotherapy provokes a coordinated senescence and inflammatory response that current epigenetic clocks largely miss.

The authors are careful about the limits of their analysis. The longitudinal component was exploratory and small; the cross-sectional and longitudinal cohorts differed in age and sampling protocols; p16 and methylation were measured in different biological compartments; and chemotherapy-related shifts in immune cell composition can confound whole-blood methylation measures. The three-to-six-month follow-up window may also simply be too short for clocks that evolve over years. Treatment regimens were heterogeneous, mixing anthracycline and non-anthracycline approaches, though recent long-term follow-up found persistently elevated p16 regardless of regimen.

Even so, the message is clear and potentially consequential: the most popular biomarkers of biological aging are not interchangeable. Choosing between them requires knowing which aging process—and which timescale—a study actually cares about. For the millions of breast cancer survivors living with the long-term consequences of treatment, that distinction could shape how researchers track accelerated aging, design interventions such as exercise or senolytic drugs, and ultimately judge whether a therapy that cures cancer is also quietly aging the body that carries it.

Subject of Research: Comparison of cellular senescence marker p16INK4a and DNA methylation epigenetic clocks as biomarkers of biological aging in women with early breast cancer treated with chemotherapy

Article Title: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer

Article References: p16INK4a and DNA methylation clocks in women treated with chemotherapy for early breast cancer. (n.d.). https://doi.org/10.1007/s11357-026-02521-3

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02521-3

Keywords: p16INK4a, DNA methylation clocks, biological aging, cellular senescence, breast cancer, chemotherapy, epigenetic age, GeroScience, GrimAge, PhenoAge, biomarkers of aging, cancer survivors

ARDD 2026 arrives as longevity research moves beyond speculative discussions about extending lifespan and toward a more technically defined goal: extending healthspan, the period during which people remain free from major age-related disease and disability. Researchers are increasingly studying aging as a complex biological process involving cellular senescence, chronic inflammation, mitochondrial dysfunction, impaired protein quality control, genomic instability, and changes in tissue repair. The convergence of these fields has created new opportunities for drug discovery, biomarker development, and clinical testing.

The meeting is expected to bring together academic scientists, clinical investigators, biotechnology companies, pharmaceutical executives, entrepreneurs, investors, and policymakers. Its organizers describe the event as a global forum for translating discoveries in the biology of aging into therapeutic programs. That translation remains one of the field’s central challenges: findings observed in model organisms must be validated in humans, measurable biological markers must be linked to meaningful clinical outcomes, and potential interventions must demonstrate acceptable safety over long treatment periods.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He emphasized that progress will require collaboration across disciplines and sectors. Aging biology draws on genetics, molecular biology, systems medicine, computational science, epidemiology, and clinical research, making partnerships essential for determining which mechanisms are genuinely actionable and which are only correlated with age-related decline.

Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen, said the conference’s move to Boston represents a new chapter for the meeting. Boston and the broader northeastern United States host a dense network of universities, hospitals, biotechnology companies, venture investors, and pharmaceutical research centers. The location is intended to connect longevity researchers with an ecosystem already known for developing therapies in oncology, immunology, metabolic disease, and neurology—fields that increasingly intersect with the science of aging.

The 2026 meeting will be officially organized by Insilico Medicine, with Insilico Medicine and Eli Lilly serving as Tier 1 sponsors. The McKinsey Health Institute will participate as the sole knowledge partner. Additional sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health, and TruDiagnostic. Other supporting organizations include Synaro Capital, The Cat Health Company, PranaGen Bioscience, Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity, and QuadraScope.

The breadth of this sponsor network reflects the increasingly commercial character of longevity science. Companies are developing interventions aimed at specific mechanisms associated with aging, including senescent cell accumulation, immune aging, metabolic deterioration, extracellular matrix changes, and loss of muscle strength. Others are building technologies to measure biological age using DNA methylation, proteomic signatures, glycan profiles, imaging, and functional assessments. These tools could help researchers identify high-risk individuals, select participants for clinical trials, and determine whether a treatment is altering the underlying biology rather than merely easing symptoms.

Alex Zhavoronkov, Ph.D., co-chair of ARDD and CEO of Insilico Medicine, said the meeting has served for more than a decade as a platform connecting academia, pharmaceutical companies, startups, and investors. He described the momentum surrounding the 2026 event as evidence that longevity biotechnology has become an important part of modern drug discovery and health economics. Insilico Medicine has been among the companies applying artificial intelligence to target identification and drug design, a strategy that could accelerate the search for compounds capable of modulating disease-related aging pathways.

Now in its 13th year, ARDD is presented by its organizers as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 program is expected to focus on the practical requirements of developing therapies: defining robust biomarkers, designing trials for slowly progressing conditions, identifying clinically meaningful measures of function, and establishing regulatory pathways for interventions that target aging-related biology. As the field enters a more mature phase, its credibility will increasingly depend on reproducible evidence, rigorous human studies, and the ability to show that molecular improvements translate into longer, healthier lives.

Subject of Research: Aging biology, longevity biotechnology, healthspan extension, and the translation of aging research into therapeutic drug-development programs.

Article Title: ARDD 2026 to Bring Pharmaceutical and Longevity Leaders Together in Boston

News Publication Date: August 7, 2026

Web References: agingpharma.org

Image Credits: ARDD 2026

Keywords: aging research, longevity science, healthspan, geroscience, drug discovery, biotechnology, Eli Lilly, Insilico Medicine, ARDD 2026, biological aging, senescence, biomarkers, Harvard University

Clonal hematopoiesis arises when blood-forming stem cells accumulate mutations and expand into dominant clonal populations. While such expansions are common in older adults, not all are equally risky. The key challenge has been distinguishing which biomarkers merely correlate with clonal hematopoiesis from those that reflect upstream mechanisms driving it.

To address this, the researchers leveraged OmniAge to connect aging signatures to “mitotic clocks,” molecular patterns that track the cumulative number of cell divisions over time. Instead of treating age-related omics as a static snapshot, the team modeled how division-linked processes might predict the emergence and persistence of clones.

Methodologically, the study integrates biomarker discovery with causal inference strategies. By testing whether mitotic-clock–linked features explain variation in clonal hematopoiesis beyond conventional aging measures, the authors argue for a directional relationship rather than a purely observational one.

The results suggest that mitotic clocks capture biological strain that promotes clonal selection in hematopoietic lineages. In other words, accelerated or dysregulated cell division history may create the evolutionary conditions for certain mutant clones to outcompete their neighbors.

The OmniAge framework also provides a unified resource for researchers, consolidating aging-related omics markers that can be interrogated across cohorts. This is positioned as a step toward translating biomarker panels into mechanistic hypotheses that can be tested experimentally.

Crucially, the paper frames clonal hematopoiesis not only as a marker of aging but as a downstream outcome of division-linked processes with identifiable causal footprints. That framing could sharpen risk stratification and guide future interventions aimed at preserving hematopoietic function.

If validated across diverse populations, these findings may help clinicians interpret aging biomarker readouts in terms of underlying cellular history. More broadly, OmniAge may become a template for linking multi-omic aging data to causal pathways across diseases.

Subject of Research: Aging omic biomarkers; clonal hematopoiesis; mitotic clocks; causal inference
Article Title: The OmniAge compendium of aging omic biomarkers links mitotic clocks to clonal hematopoiesis and causality.
Article References: https://doi.org/10.1038/s41467-026-76038-w
DOI: 10.1038/s41467-026-76038-w
Keywords: OmniAge; aging biomarkers; mitotic clocks; clonal hematopoiesis; causality; multi-omics

The study, released on October 22 in the prestigious journal Aging Cell, represents an expansive collaboration among scientists from the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, the University of Washington, and affiliated research institutions. Their work leverages data from almost 800 dogs enrolled in the Dog Aging Project—a comprehensive, multi-site longitudinal investigation designed to examine aging processes in dogs as a model for human health.

Central to their discovery is the dynamic landscape of metabolites in the bloodstream—the tiny molecules that orchestrate life’s biochemical symphony. Astonishingly, the researchers observed that around 40% of these circulating metabolites shift in concentration with age. Such a profound molecular remodeling underscores the intricate metabolic adjustments that accompany the aging process, providing a tangible biochemical footprint of biological senescence in these animals.

Delving deeper, the scientists spotlighted a unique family of metabolites known as post-translationally modified amino acids (ptmAAs). These rarely studied molecules arise either from the microbial alchemy within the gut or from the endogenous breakdown of proteins throughout the body. Remarkably, ptmAAs were consistently linked to aging across a diverse spectrum of dog breeds, encompassing various sizes and both sexes, suggesting a fundamental role in the physiology of aging.

The origin and physiological roles of ptmAAs remain enigmatic; however, this study implicates kidney function as a critical regulator of their levels. Kidneys act as a sophisticated filtration apparatus, purging protein catabolites and other metabolic detritus from the bloodstream. As renal efficiency wanes with age, the team discovered a corresponding accumulation of ptmAAs in the blood, offering a plausible biochemical explanation for differences in aging trajectories among individual dogs—and by extension, perhaps humans.

Importantly, this investigation did not merely rely on cross-sectional snapshots but sets the stage for longitudinal analyses that will track metabolite fluctuations within the same animals over extended periods. This continuous monitoring is vital to tease apart causality from correlation and to identify microbial populations within the gut microbiome that may drive changes in ptmAA profiles with advancing age.

In conjunction with molecular data, the researchers will integrate owner-reported metrics, particularly focusing on muscle mass trends in aging dogs. Muscle atrophy, a hallmark of aging in both humans and canines, may intertwine with metabolite changes, thus providing a holistic view of physiological decline and resilience.

The implications of this research ripple far beyond veterinary science. By decoding the molecular signatures of aging in a companion animal model both genetically and environmentally paralleling humans, scientists are propelled toward uncovering universally applicable biomarkers. Such biomarkers have unparalleled potential both to track the pace of aging and to predict future health outcomes and lifespan.

Moreover, the identification of ptmAAs as biomarkers presents new horizons in geroscience, where interventions targeting kidney function, protein metabolism, or gut microbiota composition could modify the aging process. Coupling biomarker trajectories with therapeutic trials may illuminate whether drugs or lifestyle strategies can alter the molecular clock, ultimately improving healthspan.

The Dog Aging Project’s unique framework—melding molecular biology, veterinary medicine, and owner-driven data—enables a rich integrative approach. The potential to correlate metabolite shifts to clinical markers and phenotypic changes nurtures hope for precision gerontology, where aging is no longer a black box but a quantifiable, modifiable process.

Acknowledging the intricate crosstalk between host organs and gut microbes in aging physiology is a vital part of this work’s novelty. The gut microbiome’s role in synthesizing or modifying metabolites like ptmAAs adds a new layer of complexity and therapeutic opportunity, ushering in an era where microbial ecology is integral to understanding and modulating aging.

By enrolling diverse dog breeds and sizes, the study ensures its biomarkers transcend genetic and physiological constraints, enhancing the translatability of findings to heterogeneous human populations. This breadth bolsters confidence that the mechanisms unveiled have broad biological relevance.

In the words of senior author Daniel Promislow, a renowned expert in aging biology, this research magnifies a rare chance to elucidate the causes and consequences of aging with unprecedented clarity. Insights gleaned not only promise to extend lifespan but crucially aim to enrich healthspan—that phase of life marked by vitality and freedom from chronic disease.

With continued investigations into metabolite dynamics, kidney health, and microbiome interactions, this line of inquiry charts a path toward a future where aging is monitored with molecular precision, interventions are personalized, and both humans and their canine companions enjoy prolonged years of robust health.

Subject of Research: Molecular biomarkers of aging physiology in dogs as a model for humans
Article Title: Protein Catabolites as Blood-Based Biomarkers of Aging Physiology: Findings From the Dog Aging Project
News Publication Date: 22-Oct-2025
Web References: https://doi.org/10.1111/acel.70226; https://dogagingproject.org/
References: Harrison, B.R., Promislow, D., et al. (2025). Protein Catabolites as Blood-Based Biomarkers of Aging Physiology: Findings From the Dog Aging Project. Aging Cell. DOI: 10.1111/acel.70226
Keywords: Gerontology, Metabolites, Amino Acids, Dogs